Get the Stockscreener App
8.26
0.98%
0.08
After Hours:
8.26
Kalaris Therapeutics Inc stock is traded at $8.26, with a volume of 83,665.
It is up +0.98% in the last 24 hours and up +40.36% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$8.18
Open:
$8.14
24h Volume:
83,665
Relative Volume:
0.50
Market Cap:
$154.48M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.43%
1M Performance:
+40.36%
6M Performance:
+230.40%
1Y Performance:
+0.00%
1-Day Range:
$8.025
$8.418
1-Week Range:
$7.915
$8.885
52-Week Range:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
8.26 | 152.99M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Nov-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
View All
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1% - MarketBeat
Analysts’ Weekly Ratings Updates for Kalaris Therapeutics (KLRS) - Defense World
Chardan Capital Initiates Coverage on Kalaris Therapeutics (NASDAQ:KLRS) - Defense World
Kalaris Therapeutics announces initial data from TH103 trial - MSN
Kalaris Therapeutics raises $50M privately - MSN
Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy - MarketBeat
Chardan Capital Initiates Coverage of Kalaris Therapeutics (KLRS) with Buy Recommendation - Nasdaq
Chardan Initiates Kalaris Therapeutics at Buy With $19 Price Target - marketscreener.com
Chardan Capital Markets initiates coverage on Kalaris stock with Buy rating - Investing.com Nigeria
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Why Kalaris Therapeutics Inc. stock is rated strong buyJuly 2025 Chart Watch & Real-Time Volume Triggers - Улправда
KLRS Kalaris Therapeutics Inc +8.76%eToro - eToro
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Why Kalaris Therapeutics Inc. stock is popular among millennialsJuly 2025 WrapUp & AI Powered Market Entry Strategies - Улправда
Will Kalaris Therapeutics Inc. stock deliver long term returnsJuly 2025 Momentum & Comprehensive Market Scan Reports - Улправда
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts (KLRS) - Seeking Alpha
Why retail investors pile into Kalaris Therapeutics Inc. stockLayoff News & Entry and Exit Point Strategies - DonanımHaber
Targets Report: Why Kalaris Therapeutics Inc. stock is popular among millennialsTrade Performance Summary & Smart Swing Trading Alerts - Улправда
Latham & Watkins Advises on Kalaris Therapeutics’ US$50 Million Private Placement - Legal Desire Media and Insights
Fundamentals Check: Will Kalaris Therapeutics Inc. stock outperform growth indexesJuly 2025 Reactions & Reliable Momentum Entry Alerts - Улправда
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth (KLRS) - Seeking Alpha
Kalaris stock price target raised to $26 at Citizens on TH103 data - Investing.com Canada
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing - TipRanks
Kalaris Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
Kalaris Therapeutics (NASDAQ: KLRS) lines up $50M private placement - Stock Titan
Kalaris Rises On Positive Early Data From Neovascular AMD Trial And $50Mln Financing Boost - Nasdaq
Kalaris reports positive early data for TH103 in AMD treatment By Investing.com - Investing.com Australia
Aspen Aerogels Announces Amendment to MidCap Credit Facility - The Manila Times
Vine Hill Capital Investment Corp. II Announces Pricing of Upsized $200 Million Initial Public Offering - The Manila Times
Future Mineral Announces Options Grant - The Manila Times
LACAHSA Board Approves $11.4M for Emergency Rental Assistance Funding, Bringing Total Measure A Prevention Investments to $29.5M in 2025 - The Manila Times
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement - The Manila Times
Biotech developing eye disease drug secures $50M to fund trials to 2027 - Stock Titan
Kalaris Posts Positive Results from Macular Degeneration Drug Trial - marketscreener.com
Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in nAMD - TradingView — Track All Markets
[8-K] Kalaris Therapeutics, Inc. Reports Material Event | KLRS SEC FilingForm 8-K - Stock Titan
Kalaris reports positive early data for TH103 in AMD treatment - Investing.com India
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD - The Manila Times
Kalaris Therapeutics reports positive initial Phase 1a data for TH103 - marketscreener.com
Single eye injection boosts vision in early test for macular degeneration - Stock Titan
Kalaris Therapeutics, Inc. announced that it expects to receive $49.99992 million in funding - marketscreener.com
Gold hits 5 week high – More gains aheadSector-Based Investing & Free Phenomenal Trading Returns - Bollywood Helpline
Kalaris Therapeutics Earnings Notes - Trefis
Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) Biggest Owners Are Private Equity Firms Who Got Richer After Stock Soared 51% Last Week - 富途牛牛
Kalaris Therapeutics Inc Stock Analysis and ForecastPrice Volatility Patterns & Smarter Trades Backed by Machine Learning - earlytimes.in
Kalaris Therapeutics Inc. $KLRS Shares Sold by Gilead Sciences Inc. - MarketBeat
Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms - ts2.tech
Is Kalaris Therapeutics Inc. stock a good choice for value investorsEarnings Beat & Verified High Yield Trade Plans - Newser
Kalaris Therapeutics (KLRS) Stock Analysis Report | Financials & Insights - Benzinga
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
There is no financial data for Kalaris Therapeutics Inc (KLRS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):